Mariner LLC Invests $665,000 in Structure Therapeutics Inc. (NASDAQ:GPCR)

Mariner LLC bought a new stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 24,530 shares of the company's stock, valued at approximately $665,000.

Several other large investors have also made changes to their positions in the company. Principal Financial Group Inc. boosted its stake in shares of Structure Therapeutics by 230.0% during the 3rd quarter. Principal Financial Group Inc. now owns 545,359 shares of the company's stock worth $23,936,000 after acquiring an additional 380,115 shares in the last quarter. Handelsbanken Fonder AB bought a new position in Structure Therapeutics during the fourth quarter valued at about $4,475,000. CCG Wealth Management LLC acquired a new position in shares of Structure Therapeutics in the fourth quarter valued at $4,068,000. Exome Asset Management LLC acquired a new position in shares of Structure Therapeutics in the 3rd quarter valued at $5,274,000. Finally, Candriam S.C.A. raised its position in Structure Therapeutics by 59.6% in the fourth quarter. Candriam S.C.A. now owns 215,421 shares of the company's stock worth $5,842,000 after purchasing an additional 80,421 shares in the last quarter. Institutional investors own 91.78% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on GPCR shares. HC Wainwright reissued a "buy" rating and set a $80.00 price objective on shares of Structure Therapeutics in a report on Tuesday, April 22nd. Stifel Nicolaus started coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They issued a "buy" rating and a $50.00 price objective on the stock. William Blair assumed coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They set an "outperform" rating for the company. Finally, Citigroup started coverage on Structure Therapeutics in a research note on Friday. They issued a "buy" rating and a $60.00 target price on the stock. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $78.63.

Structure Therapeutics Stock Performance

Shares of GPCR stock traded down $0.81 during mid-day trading on Monday, hitting $26.29. The company's stock had a trading volume of 61,681 shares, compared to its average volume of 919,585. The company has a market cap of $1.51 billion, a PE ratio of -35.93 and a beta of -1.35. Structure Therapeutics Inc. has a 52 week low of $13.22 and a 52 week high of $62.74. The company's fifty day simple moving average is $20.52 and its 200-day simple moving average is $27.30.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. On average, equities analysts anticipate that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.